Diagnóstica Longwood
  • esES
  • +34 976 320 638
  • M-T: 8.30-17.30 F:8.30-14.30
  • Catalog
    • Immunology and transplantation
      • HLA Typing
      • Allergy
      • Alloantibodies Detection
      • HLA-associated diseases
      • Chimerism
      • Immune response and biomarkers
      • Immunosequencing
      • Other – Immunology
    • Molecular Genetics
      • Cystic Fibrosis
      • Prenatal Diagnosis
      • Reproduction
      • Pharmacogenomics
      • Triplet Expansion
      • Genetic Panels
      • Other – Genetics
    • Hematology and blood bank
      • Blood Group Genotyping (RBC)
      • Platelet Antibody Testing
      • Thrombophilias and Hemochromatosis
      • Cryopreservation
      • Other – Hematology
    • Oncology
      • Solid Tumor
      • Oncohematology
    • Microbiology
      • Virus
      • Bacteria
      • Fungus
      • Metatranscriptomics
      • CMI Quick-Sepsis
      • DNA/RNA extraction
    • Preanalytics
      • Blood collection
      • Sampling and Extraction
      • Sample transportation
  • Company
    • Contact
    • Work with us
    • Our brands
  • Events
Login

Prolaris®

CatalogOncologySolid Tumor

Prognostic test to determine tumour aggressiveness and 10-year disease-specific mortality in patients with primary localised prostate cancer.

Prolaris is an in vitro molecular gene expression test for patients with primary prostate cancer, which allows to study the aggressiveness of the tumour and the disease-specific 10-year mortality risk. In this way, it helps in making a decision on active follow-up or the most appropriate therapy for the patient.

It is the only validated test for all Gleason scores. It stratifies patients according to the risk of metastasis in 10 years, providing greater precision to the other clinicopathological parameters (CAPRA score).

This second-generation test combines a molecular score (CCR), obtained from the analysis of the expression of 16 genes (10 genes relevant to tumour activity in the cell cycle and 6 control genes), with the clinicopathological parameters, giving rise to the Prolaris Molecular Score or Prolaris Risk Score. This score establishes whether the patient should be included in the surveillance group or in the active treatment group.

10 prostate cancer related genes (ASPM, CDC2, CDCA8, CDKN3, DTL, FOXM1, KIAA0101, NUSAP1, PRC1, TK1).

6 reference (house-keeping) genes (CLTC, PSMA1, RPL4, RPS29, SLC25A3, UBA52).

The combination of the Prolaris molecular score with clinical parameters achieves a higher prognostic accuracy than first generation tests such as Oncotype Dx Prostate and Dechipher Prostate Biopsy.

De este modo, Prolaris identifica más pacientes elegibles para seguimiento activo que los factores clínico-patológicos (Lin D W. et al 2018, PMID: 29655620). , pudiendo incluso cambiar la toma de decisión del tratamiento hasta en un 65% Thus, Prolaris identifies more patients eligible for active follow-up than clinicopathological factors (Lin D W. et al 2018, PMID: 29655620). Prolaris can even change treatment decision making in up to 65% of cases tested in prospective clinical studies (Crawford et al 2004, Shore et al 2015, Kaul S et al 2019).

Numerous European and American guidelines, some of the most important, already recommend the use of Prolaris to improve prognosis and personalised patient treatment decision-making.

This test can be easily performed in your laboratory, but you can also choose to outsource the test to our service laboratory, Citogen*:

The result is a report that summarises the patient's combined clinical risk, showing two treatment scenarios that help to better assess active treatment or follow-up.

** For more information on the Prolaris service at CItogen, please do not hesitate to contact us.

Prolaris®

ProductReferencePresentations
Prolaris®MYR-SVQ4001 test per kit

Public Documentation

  • Brochure_Prolaris_Understanding_prostate_cancer_EN_03_20
  • Brochure_Prolaris_Patient_guide_to_the_Prolaris_test_on_prostate_cancer_EN_04_22

Related products

HLA-KMR

GenDx HLA-KMR
Additional information in the monitoring of chimerism for the loss of HLA in a relapse.
  • Certificado RUO

NGSgo-MX6-1

GenDx NGSgo-MX6-1
Speed up your NGS workflow with the six-loci multiplex
  • Certificado CE
  • Certificado IVD

NGSgo-MX11-3

High quality results with the eleven-loci multiplex
  • Certificado CE
  • Certificado IVD
Oncología molecular

Oncology

Myriad Genetics
  • Certificado CE
  • Certificado IVD
  • RT-PCR
Request information - Prolaris®

    Contact with the commercial department of Diagnóstica Longwood to request information and you will allow us to contact you commercially by email or telephone, complying with the European Data Protection regulations.

    You can unsubscribe when you want, rectify or limit your data.



    I consent to the use of my data to receive information and news

    In compliance with the provisions in the regulation General of protection of data 2016/679, DIAGNOSTICA LONGWOOD informs that its e-mail address, as well as other personal data that may be included in this form form part of a treatment of personal data whose features are detailed below: The controller of such processing will be DIAGNOSTICA LONGWOOD and the purpose will be to answer the queries raised by the user and to send him/her requested information, as well as to send information and news about our company, in case he/she has authorised it. By marking the consent, you are legitimising this use. DIAGNOSTICA LONGWOOD does not pass on data to third parties. You may at any time exercise your rights of access, rectification and deletion of your data, as explained in our Privacy Policy.


    Product families

    • Molecular Genetics
      • Prenatal Diagnosis
      • Triplet Expansion
      • Pharmacogenomics
      • Cystic Fibrosis
      • Other – Genetics
      • Genetic Panels
      • Reproduction
    • Hematology and blood bank
      • Platelet Antibody Testing
      • Cryopreservation
      • Blood Group Genotyping (RBC)
      • Other – Hematology
      • Thrombophilias and Hemochromatosis
    • Immunology and transplantation
      • Alloantibodies Detection
      • HLA-associated diseases
      • Immunosequencing
      • Other – Immunology
      • Chimerism
      • Immune response and biomarkers
      • HLA Typing
    • Microbiology
      • Virus
      • Fungus
      • DNA/RNA extraction
      • CMI Quick-Sepsis
      • Metatranscriptomics
    • Oncology
      • Oncohematology
      • Solid Tumor
    • Preanalytics
      • Sampling and Extraction
      • Blood collection
      • Sample transportation

    Diagnostica Longwood

    Customer Service:
    M-T 8.30 – 17.30 / F 8.30 – 14.30
    +34 976 320 638 – info@dlongwood.com

    • Quality Policy
    • Legal Warning
    • Privacy Policy
    • Cookie policy
    • Data Protection

    2021 © Diagnóstica Longwood SL

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!

    Política de cookies

    Más información sobre nuestra política de cookies